Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-4889
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro ; volume:11 ; number:11 ; day:16 ; month:11 ; year:2020 ; pages:1-14 ; date:11.2020
Cell death & disease ; 11, Heft 11 (16.11.2020), 1-14, 11.2020
- Creator
-
Dituri, Francesco
Scialpi, Rosanna
Schmidt, Tannin A.
Frusciante, Martina
Mancarella, Serena
Lupo, Luigi Giovanni
Villa, Erica
Giannelli, Gianluigi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41419-020-03180-8
- URN
-
urn:nbn:de:101:1-2020122720272651670760
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dituri, Francesco
- Scialpi, Rosanna
- Schmidt, Tannin A.
- Frusciante, Martina
- Mancarella, Serena
- Lupo, Luigi Giovanni
- Villa, Erica
- Giannelli, Gianluigi
- SpringerLink (Online service)
Other Objects (12)
A Practical and Efficient Method for the Synthesis of Sorafenib and Regorafenib
Sorafenib : Praxisempfehlungen für optimale Therapieerfolge beim hepatozellulären Karzinom (HCC)
Autophagy modulation attenuates sorafenib resistance in HCC induced in rats
Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC
A feedback loop of PPP and PI3K/AKT signal pathway drives regorafenib-resistance in HCC
CHOP regulated by METTL14-m6A affects cell cycle arrest and regorafenib sensitivity in HCC cells
Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma
Comparative response of nine hepatoma cell lines to the four tyrosine kinase inhibitors, sorafenib, lenvatinib, regorafenib and cabozantinib
Charakterisierung eines Patientenkollektivs mit Zweitlinientherapie nach Erstlinientherapie mit Sorafenib beim fortgeschrittenen hepatozellulären Karzinom (HCC)
Proteoglycan serglycin promotes non-small cell lung cancer cell migration through the interaction of its glycosaminoglycans with CD44
Vergleichsanalyse von jüngeren vs. älteren Patienten mit hepatozellulärem Karzinom (HCC) unter Therapie mit dem Multikinaseinhibitor Sorafenib®
A Practical and Efficient Method for the Synthesis of Sorafenib and Regorafenib
Sorafenib : Praxisempfehlungen für optimale Therapieerfolge beim hepatozellulären Karzinom (HCC)
Autophagy modulation attenuates sorafenib resistance in HCC induced in rats
Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC
A feedback loop of PPP and PI3K/AKT signal pathway drives regorafenib-resistance in HCC
CHOP regulated by METTL14-m6A affects cell cycle arrest and regorafenib sensitivity in HCC cells
Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma
Comparative response of nine hepatoma cell lines to the four tyrosine kinase inhibitors, sorafenib, lenvatinib, regorafenib and cabozantinib
Charakterisierung eines Patientenkollektivs mit Zweitlinientherapie nach Erstlinientherapie mit Sorafenib beim fortgeschrittenen hepatozellulären Karzinom (HCC)
Proteoglycan serglycin promotes non-small cell lung cancer cell migration through the interaction of its glycosaminoglycans with CD44
Vergleichsanalyse von jüngeren vs. älteren Patienten mit hepatozellulärem Karzinom (HCC) unter Therapie mit dem Multikinaseinhibitor Sorafenib®
A Practical and Efficient Method for the Synthesis of Sorafenib and Regorafenib
Sorafenib : Praxisempfehlungen für optimale Therapieerfolge beim hepatozellulären Karzinom (HCC)
Autophagy modulation attenuates sorafenib resistance in HCC induced in rats
Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC
A feedback loop of PPP and PI3K/AKT signal pathway drives regorafenib-resistance in HCC
CHOP regulated by METTL14-m6A affects cell cycle arrest and regorafenib sensitivity in HCC cells
Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma
Comparative response of nine hepatoma cell lines to the four tyrosine kinase inhibitors, sorafenib, lenvatinib, regorafenib and cabozantinib
Charakterisierung eines Patientenkollektivs mit Zweitlinientherapie nach Erstlinientherapie mit Sorafenib beim fortgeschrittenen hepatozellulären Karzinom (HCC)
Proteoglycan serglycin promotes non-small cell lung cancer cell migration through the interaction of its glycosaminoglycans with CD44